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Aim To evaluate whether the T1D susceptibility locus on chromosome 16q contributes to the genetic sus-
ceptibility to T1D in Russian patients.
Method Thirteenmicrosatellitemarkers, spanning a 47-centimorgan genomic region on 16q22-q24were eval-
uated for linkage to T1D in 98 Russian multiplex families. Multipoint logarithm of odds (LOD) ratio
(MLS) and nonparametric LOD (NPL) values were computed for each marker, using GENEHUNTER
2.1 software. Four microsatellites (D16S422, D16S504, D16S3037, and D16S3098) and 6 biallelic
markers in 2 positional candidate genes, ICSBP1 and NQO1, were additionally tested for association
with T1D in 114 simplex families, using transmission disequilibrium test (TDT).
Results A peak of linkage (MLS=1.35, NPL=0.91) was shown for marker D16S750, but this was not signifi-
cant (P=0.18). The subsequent linkage analysis in the subset of 46 multiplex families carrying a com-
mon risk HLA-DR4 haplotype increased peak MLS and NPL values to 1.77 and 1.22, respectively, but
showed no significant linkage (P=0.11) to T1D in the 16q22-q24 genomic region. TDT analysis failed
to find significant association between these markers and disease, even after the conditioning for the
predisposing HLA-DR4 haplotype.
Conclusion Our results did not support the evidence for the susceptibility locus to T1D on chromosome 16q22-24
in the Russian family data set. The lack of association could reflect genetic heterogeneity of type 1 dia-
betes in diverse ethnic groups.
Susceptibility to type 1 diabetes mellitus
(T1D) is determined by multiple genetic and envi-
ronmental factors. The HLA region represents the
major T1D susceptibility locus (IDDM1) (1). How-
ever, several additional susceptibility loci, with
modest genetic effects, were also mapped (1). At
present, susceptibility genes within two of the
non-HLA susceptibility loci were clearly defined.
There are the insulin-linked variable number of tan-
dem repeats region and the cytotoxic T-lymphocyte
antigen-4, which represent the IDDM2 and IDD M12
loci, respectively (2). However, most non-HLA loci
predisposing to T1D remain undefined yet.
One of the non-HLA T1D susceptibility
loci was previously mapped to chromosome
16q22-q24 in 356 UK Caucasian multiplex fami-
lies (3). This locus spanned a 32-centimorgan (cM)
region between two polymorphic markers,
D16S515 and D16SS520, where a peak of linkage
(multipoint logarithm of odds [LOD] ratio [MLS] of
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3.4) was found for D16S3098 (3). Later, the link-
age to type 1 disease on chromosome 16q22-q24
was replicated in the extended data set of 767 US
and UK affected families, with MLS of 3.93 for
D16S3098 marker, suggesting a role of this region
in predisposition to type 1 diabetes (4). On the
other hand, genome-wide scans in Scandinavians
(5) and the Dutch (6) failed to show a linkage of
this region to the disease.
Interestingly, the T1D susceptibility lo-
cus on chromosome 16q22-q24 partially overlaps
with the susceptibility loci mapped for other auto-
immune disorders, such as celiac disease (7) and
asthma (8), suggesting that this genomic region
could harbor a common but unknown susceptibil-
ity gene for autoimmunity. Association studies of
NQO1, a positional candidate gene for suscepti-
bility, located 20 cM centromeric from D16S3098
and encoding NAD(P)H-quinone oxidoreductase
1 [EC 1.6.99.2], have produced inconsistent re-
sults (9-12). The susceptibility locus contains an-
other likely positional candidate gene, ICSBP1, sit-
uated on 16q24.1 14 cM telomeric from
D16S3098. The ICSBP1 gene encodes interferon
consensus sequence binding protein 1, a transcrip-
tion factor of the interferon regulatory family,
which is mainly expressed in cells of the immune
system and plays a key role in the maturation of
macrophages (13). No polymorphic markers within
this gene have yet been evaluated for association
with an autoimmune disease.
Since linkage studies in different popula-
tions for the 16q22-q24 locus showed conflicting
results, it would be interesting to examine whether
this locus contributes to susceptibility to T1D in
Russian affected patients. We evaluated a set of
polymorphic genetic markers, which are situated
on chromosome 16q21-q24 and include single nu-
cleotide polymorphisms (SNPs), located within the
NQO1 and ICSBP1 genes, in Russian type 1 dia-
betic families but failed to find a significant linkage
and association of these markers with T1D.
Patients and Methods
Patients
We studied 114 Russian simplex fami-
lies, each containing both parents and two siblings
(one affected with T1D (proband), diagnosed be-
fore the age of 17, and one non-diabetic sibling).
Sixteen simplex families were collected from the
Samara Diabetic Centre, the others being recruited
from the Endocrinology Research Center in Mos-
cow. Ninety-eight Russian multiplex families, con-
taining 108 affected full sib pairs, were recruited
from the Endocrinological Research Center. Of
these 98, 93 families each included both parents
and 2 affected siblings, whereas the remaining 5
families each contained both parents and 3 dia-
betic children. In simplex and multiplex families,
all parents had no diagnosed T1D. Informed con-
sent was obtained from all subjects before partici-
pation in this study. The research protocol was ap-
proved by the Ethics Committee of the Endocrinol-
ogy Research Centre and performed in accordance
with the principles of the Helsinki Declaration.
Diabetes was diagnosed according to the
criteria defined by the American Diabetes Associa-
tion (14). T1D was classified according to the pres-
ence of ketosis, low body mass index, and the need
for insulin treatment. In all subjects, diagnosis of the
disease was confirmed by the presence of at least
one of the two major islet autoantibodies: GAD65
antibodies and/or anti-tyrosine phosphate-like mol-
ecule (ICA512) antibodies (15,16). C-peptide levels
were measured in the blood serum of patients using
a commercially available radioimmunoassay (Medi-
pro AG, Teufen, Switzerland) (17). Hemoglobin A
1c
(HbA
1c
) measurements were performed using
high-performance liquid chromatography (DIAMAT,
BIO-RAD, Hercules, CA, USA). Immunological and
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Table 1. Clinical and biochemical characteristics of affected and non-affected children in Russian diabetic families
Multiplex families (n=98) Simplex families (n=114)
Characteristic affected sibs (n=201) probands (n=114) non-affected sibs (n=114)
Male/female ratio 107/94 66/48 53/61
Age, years (range) 16.5±5.7 (4-27) 19.3±4.5 (7-29) 21.1±6.3 (5-31)
Duration of diabetes, years (range) 8.3±3.2 (2.5-19) 9.5±4.3 (1.1-25)
Insulin dose, U/kg (range) 1.07±0.03 (0.93-1.15) 1.15±0.05 (0.9-1.24)
Body mass index, kg/m2 (range) 17.3±1.7 (14.2-21.6) 18.5±2.2 (13.5-22.5) 23.0±2.5 (13.1-25.1)
HbA1c, % (range) 9.1±2.4 (5.5-13.9) 9.8±2.2 (5.2-13.5) 6.5±1.4 (4.4-8.6)
Basal serum C-peptide, pmol/mL (range) 0.23±0.04 (0.11-0.36) 0.25±0.04 (0.11-0.33) 0.41±0.04 (0.35-0.55)
GAD65 antibodies-positive patients, No. (%) 156 (77) 100 (88)
ICA512 antibodies-positive patients, No. (%) 145 (72) 81 (71)
clinical characteristics of diabetic and non-affected
children are summarized in Table 1.
DNA Analysis
Genomic DNA was extracted from
whole-blood samples collected in disodium EDTA
(3 mg/ml), according to the established protocol
(18). Microsatellite markers (D16S402, D16S422,
D16S504, D16S750, D16S3037, D16S3050,
D16S3089, D16S3073, D16S3089, D16S3098,
D16S3106, D16S3118, and D16S3140) were cho-
sen from the public databases and analyzed by
PCR. Primer sequences were as described in the
Genome Database (http://www.gdb.org). For each
microsatellite marker, one primer was fluorescent-
ly labeled with either 6-HEX or FAM (Eurogentec,
Seraing, Belgium). The PCR cocktail contained 10
mM Tris-HCl pH 9.0, 50 mM KCl, 1.0-1.5 mM
MgCl
2
, 0.1% Triton X-100, 0.2 mM each dNTP,
0.5 U AmpliTaq DNA polymerase (Applied Bio-
systems, Foster City, CA, USA), 5 M each primers
and 100 ng of genomic DNA in a total volume of
10 L. PCR was carried out on a GeneAmp® PCR
System 2700 (Applied Biosystems) at 95°C for 3
minutes, followed by 30 cycles of denaturation at
95°C for 15 seconds, annealing at 55-60°C for 15
seconds and extension at 72°C for 30 seconds,
with the final extension at 72°C for 10 minutes.
Fluorescence-based genotyping was performed
with an ABI PRISM 310 DNA Sequencer (Applied
Biosystems) and GeneScan analysis software, Ver-
sion 3.1.2 (Applied Biosystems).
HLA-DRB1, -DQA1, and -DQB1 alleles
were determined by the use of a locus-specific am-
plification procedure, using a subsequent hybrid-
ization of PCR products with a corresponding al-
lele-specific oligonucleotide probe as previously
described (19,20).
Single nucleotide polymorphisms (SNPs)
located within corresponding positional candidate
genes (NQO1 and ICSBP1) were genotyped in
simplex families, using the PCR- restriction frag-
ment length polymorphism (RFLP) approach. The
Pro/Ser 187 SNP of the NQO1 gene was tested us-
ing DNA treatment with Hinf I restriction endo-
nuclease, as described earlier (11,21). The Arg/Trp
139 polymorphism of the NQO1 gene was de-
tected using DNA digestion with Msp I restriction
enzyme as described by Sanyal et al (22). Other
SNPs were taken from the dbSNP database
(http://www.ncbi.nlm.nih.gov/SNP/). PCR-RFLP
assays for detection of each SNP are described in
Table 2. All restriction enzymes used were manu-
factured in Fermentas (Vilnius, Lithuania). Follow-
ing digestion, DNA products were separated in a
2% agarose gel with ethidium bromide.
Statistical Analysis
Multipoint linkage analysis was per-
formed in affected sibling pairs from multiplex
families using GENEHUNTER 2.1 software (23).
MLS and nonparametric LOD (NPL) values were
computed using allele frequencies derived from
parents of the affected siblings, assuming the dom-
inance variance exists. Marshfield sex-average
map distances were used in the linkage analysis
(24). According to criteria for mapping genes in-
volved in complex traits proposed by Lander and
Kruglyak (25), a LOD score of 2.2 was considered
to indicate a suggestive linkage, whereas a LOD
score of 3.6 was assessed as an evidence for signif-
icant linkage.
Using the GENEHUNTER software, the
transmission disequilibrium test (TDT) was per-
formed in simplex families to identify alleles pref-
erentially transmitted from heterozygous parents
to diabetic offspring (26). Chi-square test was used
to estimate whether the allele transmission signifi-
cantly differed from the random pattern (1:1). P
value (P
c
) of less than 0.05, after correction for
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Table 2. Description of molecular assays to detect SNPs within three candidate genes studied for association with susceptibility to
type 1 diabetes mellitas (T1D) in a Russian sample
SNP dbSNP ID Gene
Location within the
gene (position from the
transcription start, bp) PCR primers, 5'3'
Annealing
temperature,
°C ([Mg2+],
mM)
Restriction
enzyme to
digest a
PCR product
Digestion
temperature,
(°C)
Duration of
digestion,
(hours)
Definition of
alleles (length
of digestion
products, bp*)
A/G 689453 NQ01 exon 2: codon 24 (72) F:GTCCTTCAACTATGCCATGAAGGC
R:CTCCTCCTACCTGTGATGTCC
65 (1.0) Pvu II 37 3 G allele: 135
A allele: 109+26
C/T 8052064 ICSBP1 exon 3: codon 138 (414) F:GATCAGCTCGTCGATTTCAGAGCGAT
R:GTGATGCCTCCGTGCCATGTGTC
65 (1.0) Pvu I 37 3 C allele: 11+24
T allele: 141
T/C 11545564 ICSBP1 exon 2: codon 100 (300) F: CTGGAAGGTTTCATGCCCATA
R: CACTTGGAAGACGAGGTTAC
60 (1.5) Pvu II 37 3 T allele: 164
C allele: 9+73
C/T 2280378 ICSBP1 intron 6 (16124) F: GGCTGGAGCAGGGCCTCAGACTCGA
R: CATCAGGTGATTGTCGGGAGCC
65 (1.5) Aat II 37 3 C allele: 88+28
T allele: 116
*bp – base pair.
multiple alleles (20), was considered significant.
For each microsatellite marker, an overall TDT P
value was also calculated. For each SNP, P value
was multiplied by a total number of alleles tested
(6) to obtain a corrected P value (P
c
).
Results
Multipoint Linkage Analysis
Thirteen microsatellite markers, span-
ning a distance about 49 cM on chromosome
16q22-q24, were analyzed for linkage with T1D
in Russian multiplex families. This genomic re-
gion lies between D16S3140 and D16S3037 (sit-
uated 74.44 cM and 121.45 cM, respectively,
from the p-terminus) and includes a 32-cM sus-
ceptibility locus for type 1 diabetes mapped to
chromosome 16q22-q24 in UK families (3). Three
markers, D16S422, D16S3037, and D16S3098,
which showed significant linkage to diabetes in
previous studies (3,4), were also evaluated in our
investigation.
The peak of linkage (MLS=1.35,
NPL=0.91) was found for D16S504 located 7.1
cM apart from D16S3098, a marker that demon-
strated maximum strength of linkage to T1D in UK
Caucasians (3), but not in our study (P=0.18) (Fig.
1 and 2). However, a MLS value observed in our
study did not reach a MLS threshold of 2.2 that rep-
resents suggestive linkage (25). This, suggests a
lack of linkage of the studied markers to type 1 dia-
betes in the Russian family data set. Further link-
age analysis of the susceptible HLA-DR4 haplo-
type (DRB1*04-DQB1*0302) was performed in a
subset of 46 affected sibling pairs carrying this
haplotype. DR4 represents the most common HLA
class II risk haplotype for type 1 diabetes in the
Russian multiplex family data set (27-29). The
HLA-conditioning linkage analysis resulted in in-
creasing the maximum MLS and NPL to 1.77 and
1.22, respectively, for D16S504 marker (P=0.11)
(Figs. 1 and 2). The MLS value still did not reach
the cut-off value of 2.2, showing no significant
linkage between markers on 6q22-q24 and T1D in
the Russian family data set.
Transmission Disequilibrium Test
However, a lack of linkage between a
marker and disease does not consequently suggest
a lack of association of the marker with the dis-
ease. Therefore, we estimated transmission of al-
leles of the peak marker D16S504 and three micro-
satellites (D16S422, D16S3037, and D16S3098)
which displayed a significant relationship to T1D in
UK Caucasians (3,4). The TDT analysis was per-
formed in the independent set of 114 Russian sim-
plex families. Among these markers, the signifi-
cance in preferential transmission of some alleles
673
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Figure 1. Multipoint logarithm of odds (LOD) ratio (MLS)
plot for type 1 diabetes on chromosome 16q22-q24, ob-
tained using the “estimate” command of GENEHUNTER
2.1, assuming that dominance variance exists, and using
allele frequencies from parents of affected sibs in 98 Rus-
sian diabetic multiplex families (solid line) and in a subset
of 46 multiplex families, carrying the common risk
HLA-DR4 haplotype (dashed line). Dotted line indicates
the suggestive level of linkage, with a LOD score that is
equal or more than 2.2 (25). A scale of genetic distances
between the markers is shown in centimorgans, according
to the Marshfield sex-average map (24).
Figure 2. Multipoint non-parametric logarithm (NPL) pro-
file for type 1 diabetes on chromosome 16q22-q24, ob-
tained using the “estimate” command of GENEHUNTER
2.1, assuming that dominance variance exists, and using
allele frequencies from parents of affected sibs in 98 Rus-
sian diabetic multiplex families (solid line) and in a subset
of 46 multiplex families carrying the common risk HLA-
DR4 haplotype (dashed line). A scale of genetic distances
between markers is presented in centimorgans, according
to the Marshfield sex-average map (24).
from parents to diabetic offspring was preliminary
observed (Table 3). However, after correction for
multiple alleles, no significance was observed.
Further conditioning for the predisposing HLA-
DR4 haplotype could also not reveal the signifi-
cance in preferential allele transmission from par-
ents to probands in the subset of 42 simplex fami-
lies, each including a proband with the DR4
haplotype (Table 3). Hence, these results showed
the lack of association between the studied micro-
satellite markers and T1D in the Russian simplex
families.
In addition, we evaluated by TDT analy-
sis 6 SNPs located within two positional candidate
genes, NQO1 and ICSBP1, on chromosome
16q22-q24 (3 SNPs in each gene). No significant
difference in the allele transmission was shown,
suggesting that these markers are not associated
with T1D in the family data set, even when strati-
fied for the common HLA risk haplotype (Table 4).
Discussion
We tested 12 microsatellite markers, lo-
cated within the putative T1D susceptibility locus
674
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Table 3. Transmission disequilibrium test of of polymorphic markers D16S422, D16S540, D16S3073, and D16S3098 in 114 Rus-
sian type 1 diabetic simplex families and in the subset of 42 simplex families, with a proband carrying the predisposing HLA-DR4
haplotype
All simplex families (n=114) Simplex families with the HLA-DR4 haplotype (n=42)
Allele probands non-affected sibs probands non-affected sibs
length, bp* T† NT§ 21 P Pc T† NT§ 21 P T† NT§ 21 P Pc T† NT§ 21 P Pc
D16S504
268 19 24 1.16 0.28 25 18 2.28 0.13 11 14 0.72 0.40 15 10 2.0 0.16
274 1 2 0.67 0.41 1 2 0.67 0.41 0 0 0.00 1.00 0 0 0.00 1.00
276 11 12 0.09 0.77 14 9 2.17 0.14 5 6 0.18 0.67 5 6 0.18 0.67
280 29 16 7.51 0.01 >0.05 18 27 3.60 0.06 16 9 3.92 0.05 >0.05 10 15 2.0 0.16
282 11 16 1.85 0.17 13 14 0.07 0.79 3 6 2.00 0.16 5 4 0.22 0.64
Overall (df=4) 5.63 0.23 4.39 0.36 3.41 0.49 2.20 0.70
D16S3073
176 4 9 3.84 0.05 >0.05 8 5 1.38 0.24 3 4 0.29 0.59 4 3 0.29 0.59
178 17 19 0.22 0.64 18 18 0.00 1.00 6 10 2.00 0.16 9 7 0.50 0.48
180 40 26 5.94 0.01 >0.05 29 37 1.94 0.16 17 10 3.63 0.06 12 15 0.67 0.41
182 24 31 1.78 0.18 30 25 0.91 0.34 10 12 0.36 0.55 11 11 0.00 1.00
Overall (df = 3) 5.89 0.12 2.12 0.54 3.14 0.37 0.73 0.87
D16S3098
157 33 36 0.61 0.43 39 30 2.35 0.13 13 13 0.00 1.00 15 11 1.23 0.27
159 18 24 1.71 0.19 22 20 0.19 0.66 9 11 0.40 0.53 10 10 0.00 1.00
161 12 12 0.00 1.00 10 14 1.33 0.25 4 7 1.64 0.20 6 5 0.18 0.67
163 21 15 2.00 0.16 14 22 3.56 0.06 11 7 1.78 0.18 7 11 1.78 0.18
165 3 0 6.00 0.01 > 0.05 2 1 0.67 0.41 1 0 2.00 0.16 0 1 2.00 0.16
Overall (df=4) 4.99 0.29 4.05 0.40 2.91 0.57 2.60 0.63
D16S422
188 4 8 2.67 0.10 7 5 0.67 0.41 2 2 0.00 1.00 2 2 0.00 1.0
200 40 31 2.28 0.13 34 37 0.25 0.62 18 12 2.4 0.12 11 19 4.26 0.04 >0.05
202 8 5 1.38 0.24 5 8 1.38 0.24 3 3 0.00 1.00 4 2 1.33 0.25
206 10 10 0.00 1.00 12 8 1.60 0.21 5 7 0.67 0.41 6 6 0.00 1.00
208 17 26 3.77 0.05 21 22 0.05 0.83 8 11 0.95 0.33 12 7 2.63 0.10
210 1 0 2.00 0.16 1 0 2.00 0.16 0 0 0.00 1.00 0 0 0.00 1.00
Overall (df=5) 6.95 0.22 2.98 0.70 1.99 0.85 4.1 0.54
*bp – base pair.
†T – transmitted.
§NT –not transmitted.
Table 4. Transmission disequilibrium test of SNPs within the NQO1 and ICSBP1 in 114 Russian type 1 diabetic simplex families and
in the subset of 42 simplex families, with a proband, carrying the predisposing HLA-DR4 haplotype
All simplex families (n=114) Simplex families with the HLA-DR4 haplotype (n=42)
probands
non-affected
sibs probands
non-affected
sibs
Gene SNP Allele T* NT† 21 P Pc T* NT
†

2
1 P T* NT
†

2
1 P Pc T
a NTb 21 P Pc
NQ01 A/G 72 Ser 16 18 0.24 0.62 17 17 0 1.0 9 6 1.2 0.27 10 5 3.33 0.068
NQ01 Arg/Trp 139 Trp 53 44 1.67 0.2 47 50 0.19 0.66 25 19 1.64 0.2 20 24 0.73 0.39
NQ01 Pro/Ser 187 Ser 49 41 1.42 0.23 46 44 0.09 0.77 26 20 1.57 0.21 18 28 4.35 0.037 >0.05
ICSBP1 C/T 414 T 22 20 0.19 0.66 23 19 0.76 0.38 9 10 0.11 0.74 9 10 0.11 0.74
ICSBP1 T/C 300 C 9 4 3.85 0.05 >0.05 5 8 1.38 0.24 6 2 4.0 0.046 >0.05 4 4 0 1.0
ICSBP1 C/T 16124 T 59 47 2.72 0.10 50 56 0.68 0.41 31 27 0.55 0.46 26 32 1.24 0.27
*T – transmitted.
†NT – not transmitted.
on chromosome 16q22-q24, but found no signifi-
cant evidence for their linkage and association
with the disease in the Russian family data set. Ad-
ditionally, we examined 6 polymorphic nucleo-
tide substitutions from two positional candidate
genes, ICSBP1 and NQO1. The ICSBP1 gene was
chosen because of the crucial role of its protein
product in the differentiation and maturation of
macrophages, antigen-presenting dendritic cells,
and Langerhans cells (13,30). NAD(P)H-quinone
oxidoreductase 1, a product of the NQO1 gene,
detoxifies quinones derived from the oxidation of
phenolic metabolites of benzene. The enzyme is
therefore involved in chemoprotection and plays a
role in antioxidant defense via generation of anti-
oxidant forms of ubiquinone and vitamin E (31).
Since the oxidative stress is likely to be involved in
-cell destruction (32), NQO1 is considered as a
candidate gene for T1D susceptibility.
Among 3 SNPs tested in the NQO1
gene, 2 (Pro/Ser 187 and Arg/Trp 139) represent
functionally relevant amino acid substitutions.
Ser187 and Trp139 molecular variants of NAD
(P)H-quinone oxidoreductase 1 are shown to be
less active than the wild-type enzyme (21,33).
Both common NQO1 polymorphisms have been
widely evaluated for association, with a variety of
diseases, including type 1 diabetes. However, no
association of the codon 187 dimorphism with dia-
betes was found in affected Danish families (11).
We also showed the lack of association between
Pro/Ser 187 and Arg/Trp 139 variants of the NQO1
gene and T1D in Russian simplex families (Table 4).
We could not find reports of the relation-
ship between genetic variations within another po-
sitional candidate gene for susceptibility to T1D on
chromosome 16q24, ICSBP1, and any complex
trait or disease have been presented yet. In this
study, therefore, we first analyzed 3 SNPs in the
ICSBP1 gene for relation to T1D, but found no as-
sociation with the disease.
Our data are consistent with the results
of genome-wide scans for susceptibility to type 1
diabetes in Scandinavians (5) and the Dutch (6),
showing no evidence for the T1D susceptibility
locus in 6q22-q24,
In various populations, the evidence for
linkage to T1D has been reported for more than 20
loci (1). However, the majority of originally identi-
fied loci was not reproduced in later and larger ge-
nome-wide scans (3,5,34-36). This is particularly
characteristic for minor susceptibility loci and
could reflect genetic heterogeneity of type 1 dia-
betes in diverse ethnic groups (5). The susceptibil-
ity locus on 16q22-q24 seems to represent a locus
with minor or intermediate genetic effect, for
which a sib risk (
s
) of 1.6 was obtained in UK fam-
ilies (3). Thus, it is not surprising that this suscepti-
bility locus on the chromosome 16q22-q24 was
not found in the Russian family data set.
Complex and heterogeneous genetic
background is a typical feature of multifactorial
disorders, which include a variety of autoimmune,
metabolic, and neurological diseases. For exam-
ple, whole-genome screens for loci predisposing
to autoimmune diseases, such as multiple sclero-
sis, rheumatoid arthritis, and others, conducted in
different populations identified discrete chromo-
somal regions potentially harboring susceptibility
genes. However, with the exception of the HLA lo-
cus on 6p21, no single locus generated over-
whelming evidence of linkage (37,38). These re-
sults suggest a complex genetic etiology, includ-
ing multiple genes of small to moderate effect and
probable genetic heterogeneity.
Ethnic differences, where the proportion
of individuals with a particular gene variant is dif-
ferent between human populations, also influence
the genetic effects of complex diseases (39). Dif-
ferentiated environments and life-styles in geo-
graphically separated populations greatly affect
quantitative genetic effects by enhancing or negat-
ing contribution of genes responsible for the com-
plex trait. So, studies in separate populations
should help in our understanding of genetic heter-
ogeneity of complex disorders, such as type 1 dia-
betes, by revealing common and ethnically spe-
cific genetic variants responsible for susceptibility
or resistance to the disease.
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